Taxotere containing docetaxel is a chemotherapy drug manufactured and marketed by Sanofi-Aventis, popularly used in the United States and other countries and first approved by the U.S. Food and Drug Administration (FDA) in 1996.
Taxotere acts as a microtubule inhibitor and indicated for treatment of Breast Cancer, Non-Small Cell Lung Cancer, Hormone Refractory Prostate Cancer, Gastric Adenocarcinoma and Squamous Cell Carcinoma of the Head and Neck Cancer but doctors prescribe this drug mainly to treat the breast cancer cases in the U.S making it the most prescribed drug in its class.
Taxotere has disfiguring side effects with permanent hair loss, also called as Alopecia which severely decreased their quality of life, affected body image and caused depression and distress along with other side effects including Cutaneous reactions, Neurologic reactions, Eye disorders.
The company Sanofi was aware by the year 2005 about the results of a trial of GEICAM 9805 which was sponsored by Sanofi in the late 1990s, that 9.2% of women who used the drug Taxotere suffered permanent alopecia. In spite of that Sanofi, manufacturer misled the public by falsely assuring them that hair would grow back after chemotherapy.